CABA
NASD Cabaletta Bio, Inc.$1.89 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.89, $0.08 below the day’s high of $1.97
- YTD change
- -13.70%
- vs 20-day SMA
- -28.14%
- vs 200-day SMA
- -35.21%
Price ranges
Price & Performance
-0.79 (-29.48%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 92.8% away from all-time highs of $26.35
- CABA is down 14% since the beginning of the year
- CABA is down 18% over the past 12 months
- CABA is down 43% over the past 1 month
- 16% of all CABA investors are betting against CABA
CABA reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -18.2%.
- Previous minute
- +$0.00
- Last hour
- +$0.01
- Last 5 days
- -14.86%
- vs 8-day SMA
- -12.63%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.